WSWei Song

Wei Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Song has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Huiquan Gao

    Shandong Univ Tradit Chinese Med, Grad Sch, Jinan, Peoples R China

    2 shared publications
  • Yanzhen Wan

    Qingdao Univ, Clin Lab, Qingdao Women & Childrens Hosp, Qingdao, Peoples R China

    2 shared publications
  • Hongxia Ma

    Shandong First Med Univ & Shandong Acad Med Sci, Tai An, Shandong, Peoples R China

    1 shared publication
  • Hui-Quan Gao

    Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China

    1 shared publication
  • Tao Huang

    970 Hosp PLA, Dept Radiol, Weihai, Peoples R China

    1 shared publication
  • Wei Jiang

    Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China

    1 shared publication

Latest Publications

  • Open Access

    Compound Taxus exerts marked anti-tumor activity and radiosensitization effect on hepatocellular carcinoma cells

    by Hui-Quan Gao, Xiang-Mao Bu, Wei Jiang, Yan-Zhen Wan, Wei Song


  • Open Access

    Neuroendocrine tumor of thoracic spine: case report and literature review

    by Huiquan Gao, Yanzhen Wan, Hongxia Ma, Tao Huang, Wei Song

    Neuroendocrine tumors (NETs) generally arise from endocrine cells of gut and bronchi. Primary NETs of spine are extremely rare and have been described in cervical spine, lumbar spine, sacrum, and coccyx. So far, primary NETs in thoracic spine have not been reported yet. Here we described a 46-year-old Chinese woman with NET in thoracic spine. Neuroimaging revealed a mass behind the vertebral body of T11, abnormal changes in the adnexa and surrounding soft tissue and compression of the spinal cord. She received a total resection of the tumor and T11 corpectomy. Histopathological examination and immunohistochemical staining proved the tumor to be a rare spinal NET. PET-CT and other examinations ruled out the existence of tumors in any other site. So, she was diagnosed with NET of thoracic spine. The patient received postoperative etoposide and nedaplatin chemotherapy for four cycles, and she recovered well with no evidence of tumor recurrence or metastasis during six-month medical follow-up. Spine location of NETs should be first considered as a metastatic disease unless there is proof ruling out the possibility. Complete tumor resection is the most effective therapy in NETs of spine and should be considered in priority, and chemotherapy and radiotherapy should be considered on an individual basis.


  • The Role of Cholinesterase in Differential Diagnosis between Gastric Cancer and Benign Gastric Diseases

    by Huiquan Gao, Yanzhen Wan, Xiaoyi Fan, Yanyu Dong, Xiaona Ji, Wei Song

    Background: Gastric cancer is the fifth most common malignancy worldwide. In early stages, no obvious symptoms are usually observed in gastric cancer patients, and it is especially hard to distinguish gastric cancer from benign gastric diseases, resulting in delayed diagnosis and poor prognosis. Common biomarkers of gastric cancer, such as CEA and CA19-9, are also elevated in benign diseases. There is an urgent need to develop a convenient and reliable biomarker for differentiating between gastric cancer and benign gastric diseases. Methods: This study retrospectively analyzed the data of 126 patients, including 73 gastric cancer patients and 53 benign gastric disease patients. Patient characteristics collected for analysis included age, gender, laboratory data, and clinical staging. Unpaired t-test was used to check the difference of cholinesterase level between the gastric cancer group and the benign gastric disease group. Kruskal Wallis H test and Mann-Whitney U test were used to check the difference of cholinesterase level among different stage groups. Receiver operating characteristic (ROC) curve was used to assess whether cholinesterase level can be used as a biomarker for differentiating between gastric cancer and benign gastric diseases. Results: Serum cholinesterase level was decreased significantly in the gastric cancer group in comparison to that of the benign gastric disease group (p < 0.001). In addition, cholinesterase level of stage IV patients was significantly lower than stage I patients. ROC curve analysis revealed that with a cutoff of 5,969.00 U/L, cholinesterase level showed an area under the curve of 0.819 (95% CI 0.732 - 0.905, p < 0.001) in differentiating between gastric cancer and benign gastric diseases. No significant difference in the levels of CEA and CA19-9 was observed between gastric cancer patients and benign gastric disease patients. Conclusions: This study indicated that serum cholinesterase level could be considered as a potential biomarker for differentiating between gastric cancer and benign gastric diseases.